Emerging Vector-Borne Diseases in North America

David Shahbodaghi, MD, MPH
Nicholas Rathjen, DO

American Family Physician. 2026;114(5):513-518.

Author Disclosure: No relevant financial relationships.

This clinical content conforms to AAFP criteria for CME.

Patient information: A handout on this topic is available.

Vector-borne diseases are a significant and growing public health concern. They account for approximately 20% of infectious diseases globally and cause more than 700,000 deaths each year. These diseases are caused by viral, bacterial, or parasitic pathogens most commonly transmitted through the bites of infected mosquitoes and ticks. In the United States, emerging viral infections include West Nile, dengue, chikungunya, and Zika; emerging bacterial infections include human monocytic ehrlichiosis, human granulocytic anaplasmosis, and Rocky Mountain spotted fever. Bacterial infections often require early recognition and prompt treatment with doxycycline. Increasing incidence of vector-borne diseases is closely linked with environmental changes, climate shifts, urbanization, and increased interaction with vector habitats. Preventive strategies include minimizing skin exposure with appropriate clothing, using insecticide-treated bed nets, and applying insect repellents containing 20% to 30% N, N-diethyl-m-toluamide (DEET) or 20% picaridin. Applying permethrin to clothing provides additional protection. Because many vectors are active during the day—particularly Aedes mosquitoes and most ticks—protective measures should extend beyond nighttime exposure.

See related editorial.

Vector-borne diseases are caused by viral, bacterial, or parasitic pathogens transmitted through bites, most commonly mosquitoes and ticks. Globally, vector-borne diseases account for approximately 20% of infectious diseases and cause more than 700,000 deaths each year.1 Emerging and reemerging vector-borne diseases, defined as those gaining prevalence or with rapidly expanding geographic distribution, are a significant and growing public health concern.2

In the past 20 years, environmental changes, climate shifts, and the development of previously uninhabited regions has led to the rapid emergence of vector-borne diseases (eg, West Nile virus, Zika virus) in the Western Hemisphere2 (Table 13–9). The increasing range of human activity, driven by population growth, deforestation, and expanded access to recreational activities such as camping and adventure tourism, has also made exposure and infection more likely.10 Additional vector-borne diseases not discussed in this article are listed in eTable A. Malaria (transmitted by the Anopheles mosquito) was the focus of a previous American Family Physician article and is not included in this review.11

TABLE 1. Emerging Vector-Borne Diseases in North America

Disease Region Incubation period Treatment Vector Clinical presentation Rash description Notes
Mosquito-borne viruses              
West Nile3 Endemic in all 48 contiguous states 2–14 days Supportive care; oral and intravenous hydration with antipyretic therapies Culex mosquito Flulike symptoms (eg, fever, headache, muscle weakness, arthralgia) and rash Maculopapular on trunk, arms, and legs Neuroinvasive disease (eg, meningitis, encephalitis, acute flaccid paralysis) occurs in < 1% of infections but has significant morbidity
Dengue4 Southern United States; tropical climates (American Samoa, Puerto Rico, US Virgin Islands) 4–7 days Supportive care Aedes mosquito High fever, severe myalgia and arthralgia, rash, bleeding; dengue hemorrhagic fever can also occur Erythematous and confluent with islands of unaffected skin; petechiae may be present around sites of compression Dengvaxia is the only vaccine available in the United States; however, the manufacturer has stopped production citing low demand
Chikungunya5 Southern United States; tropical climates 3–7 days Supportive care Aedes mosquito High fever, severe arthralgia, rash, headache Maculopapular The live vaccine (IXCHIQ; not available in the United States) may be administered to those ≥ 18 years traveling to endemic areas for cumulative 6 months or those > 65 years with underlying medical conditions; the recombinant vaccine (Vimkunya) is approved for those ≥ 12 years who are traveling to an endemic area

Persistent, debilitating joint pain lasting weeks to months after initial infection is common

Can also spread via blood transfusions and handling of blood products
Zika6 Southern United States; tropical climates 3–14 days Supportive care Aedes mosquito Flulike symptoms (eg, fever, arthralgia, nonpurulent conjunctivitis) and rash Maculopapular Most cases (80%) are asymptomatic

Complications include Guillain-Barré syndrome, encephalopathy, myelitis, uveitis, and thrombocytopenia

Can be sexually transmitted by men and may cause birth defects
Tick-borne              
Rocky Mountain spotted fever (Rickettsia rickettsii)7 United States, especially southeast and central states 3–12 days Doxycycline, 100 mg twice daily, for 7–10 days American dog tick (Dermacentor variabilis)

Rocky Mountain wood tick (D andersoni)
Flulike symptoms (eg, fever, headache, nausea) and rash Maculopapular; affects whole body and can include palms and soles Rash usually starts 2–4 days after fever

Early initiation of doxycycline is critical; delays can lead to severe disease and increased mortality
Human monocytic ehrlichiosis (Ehrlichia chaffeensis)8 Southeastern and south central United States 5–14 days Doxycycline, 100 mg twice daily, for a minimum 10 days Lone Star tick (Amblyomma americanum) Flulike symptoms (eg, fever, headache, chills) Maculopapular Leukopenia and thrombocytopenia are hallmarks
Human granulocytic anaplasmosis (Anaplasma phagocytophilum)9 Northeast and Mid-Atlantic United States 5–10 days Doxycycline, 100 mg twice daily, for a minimum of 10 days Deer tick (Ixodes scapularis) Flulike symptoms (eg, fever, headache, chills) — Leukopenia and thrombocytopenia; elevated liver enzymes

Information from references 3 – 9.

DAVID SHAHBODAGHI, MD, MPH, FAAFP, is a tropical and travel medicine subject matter expert for the US Army Reserve; a clinical assistant professor at Texas A&M University, College Station; and the chief medical officer at Haskell Memorial Hospital, Haskell, Texas.

NICHOLAS RATHJEN, DO, FAAFP, is a fellow in the Leader and Faculty Development Fellowship at Madigan Army Medical Center, Joint Base Lewis-McChord, Washington; an assistant professor in the Department of Family Medicine at the Uniformed Services University of the Health Sciences, Bethesda, Maryland; and a clinical instructor in the Department of Family Medicine at the University of Washington School of Medicine, Seattle.

See related editorial on page 457.

Address correspondence to David Shahbodaghi, MD, MPH, at drshahbodaghi@hmhhealth.org.

Author Disclosure: No relevant financial relationships.

  1. 1.World Health Organization. Vector-borne diseases. September 26, 2024. Accessed July 28, 2026. http://www.who.int/mediacentre/factsheets/fs387/en/​
  2. 2.Chala B, Hamde F. Emerging and re-emerging vector-borne infectious diseases and the challenges for control: a review. Front Public Health. 2021;9:715759.
  3. 3.Centers for Disease Control and Prevention. West Nile virus. Accessed April 28, 2025. https://www.cdc.gov/west-nile-virus/index.html​
  4. 4.Centers for Disease Control and Prevention. Dengue. Accessed April 28, 2025. https://www.cdc.gov/dengue/index.html​
  5. 5.Centers for Disease Control and Prevention. Chikungunya virus. June 22, 2026. Accessed September 10, 2026. https://www.cdc.gov/chikungunya/about/index.html​
  6. 6.Centers for Disease Control and Prevention. Zika virus. Accessed April 28, 2025. https://www.cdc.gov/zika/index.html​
  7. 7.Centers for Disease Control and Prevention. Rocky Mountain spotted fever. May 15, 2024. Accessed April 28, 2025. https://www.cdc.gov/rocky-mountain-spotted-fever/about/index.html​
  8. 8.Centers for Disease Control and Prevention. Ehrlichiosis. May 15, 2024. Accessed April 28, 2025. https://www.cdc.gov/ehrlichiosis/about/index.html​
  9. 9.Centers for Disease Control and Prevention. Anaplasmosis. September 4, 2024. Accessed April 28, 2025. https://www.cdc.gov/anaplasmosis/about/index.html​
  10. 10.de Souza WM, Weaver SC. Effects of climate change and human activities on vector-borne diseases. Nat Rev Microbiol. 2024;22(8):476-491.
  11. 11.Shahbodaghi SD, Rathjen NA. Malaria: prevention, diagnosis, and treatment. Am Fam Physician. 2022;106(3):270-278.
  12. 12.Centers for Disease Control and Prevention. CDC Yellow Book. July 28, 2026. Accessed September 10, 2026. https://www.cdc.gov/yellow-book/hcp/contents/index.html​
  13. 13.Sanford C, McConnell A, Osborn J. The pretravel consultation. Am Fam Physician. 2016;94(8):620-627.
  14. 14.Laroche M, Weeks ENI. Vector-borne bacterial diseases: a neglected field of infectious diseases research. Med Vet Entomol. 2023;37(2):177-178.
  15. 15.Singh P, Khatib MN, Ballal S, et al. West Nile virus in a changing climate: epidemiology, pathology, advances in diagnosis and treatment, vaccine designing and control strategies, emerging public health challenges—a comprehensive review. Emerg Microbes Infect. 2025;14(1):2437244.
  16. 16.Brüssow H, Figuerola J. The spread of the mosquito-transmitted West Nile virus in North America and Europe. Microb Biotechnol. 2025;18(3):e70120.
  17. 17.Centers for Disease Control and Prevention. West Nile virus historic data (1999–2025). June 3, 2026. Accessed July 28, 2026. https://www.cdc.gov/west-nile-virus/data-maps/historic-data.html​
  18. 18.Zou S, Foster GA, Dodd RY, et al. West Nile fever characteristics among viremic persons identified through blood donor screening. J Infect Dis. 2010;202(9):1354-1361.
  19. 19.Huntington MK, Allison J, Nair D. Emerging vector-borne diseases. Am Fam Physician. 2016;94(7):551-557.
  20. 20.Petersen LR, Brault AC, Nasci RS. West Nile virus: review of the literature. JAMA. 2013;310(3):308-315.
  21. 21.Kularatne SA, Dalugama C. Dengue infection: Global importance, immunopathology and management. Clin Med (Lond). 2022;22(1):9-13.
  22. 22.Tsheten T, Clements ACA, Gray DJ, et al. Clinical predictors of severe dengue: a systematic review and meta-analysis. Infect Dis Poverty. 2021;10(1):123.
  23. 23.Ginsburg S, May-Smith E, Smith E, et al. The eyes cannot see what the mind does not know: autochthonous dengue in South Florida. J Am Coll Emerg Physicians Open. 2025;6(1):100003.
  24. 24.Rathjen NA, Shahbodaghi SD. The ill returning traveler. Am Fam Physician. 2023;108(4):396-403.
  25. 25.Rigau-Pérez JG, Laufer MK. Dengue-related deaths in Puerto Rico, 1992–1996: diagnosis and clinical alarm signals. Clin Infect Dis. 2006;42(9):1241-1246.
  26. 26.Bartholomeeusen K, Daniel M, LaBeaud DA, et al. Chikungunya fever. Nat Rev Dis Primers. 2023;9(1):17.
  27. 27.Couzigou B, Criquet-Hayot A, Javelle E, et al. Occurrence of chronic stage chikungunya in the general population of Martinique during the first 2014 epidemic: a prospective epidemiological study. Am J Trop Med Hyg. 2018;99(1):182-190.
  28. 28.Kumar R, Ahmed S, Parray HA, et al. Chikungunya and arthritis: an overview. Travel Med Infect Dis. 2021;44:102168.
  29. 29.Centers for Disease Control and Prevention. Chikungunya vaccine. January 23, 2026. Accessed July 28, 2026. https://www.cdc.gov/chikungunya/vaccines/index.html​
  30. 30.Plourde AR, Bloch EM. A literature review of Zika virus. Emerg Infect Dis. 2016;22(7):1185-1192.
  31. 31.Centers for Disease Control and Prevention. Zika cases in the United States. July 7, 2026. Accessed July 28, 2026. https://www.cdc.gov/zika/zika-cases-us/index.html​
  32. 32.Flamand C, Fritzell C, Matheus S, et al. The proportion of asymptomatic infections and spectrum of disease among pregnant women infected by Zika virus: systematic monitoring in French Guiana, 2016. Euro Surveill. 2017;22(44):17-00102.
  33. 33.Polen KD, Gilboa SM, Hills S, et al. Update: interim guidance for preconception counseling and prevention of sexual transmission of Zika virus for men with possible Zika virus exposure—United States, August 2018. MMWR Morb Mortal Wkly Rep. 2018;67(31):868-871.
  34. 34.Centers for Disease Control and Prevention. Clinical testing and diagnosis for Zika virus disease. November 19, 2025. Accessed July 28, 2026. https://www.cdc.gov/zika/hcp/diagnosis-testing/index.html​
  35. 35.Ismail N, McBride JW. Tick-borne emerging infections: ehrlichiosis and anaplasmosis. Clin Lab Med. 2017;37(2):317-340.
  36. 36.Centers for Disease Control and Prevention. Ehrlichiosis epidemiology and statistics. February 12, 2025. Accessed December 14, 2025. https://www.cdc.gov/ehrlichiosis/data-research/facts-stats/index.html​
  37. 37.Ismail N, Bloch KC, McBride JW. Human ehrlichiosis and anaplasmosis. Clin Lab Med. 2010;30(1):261-292.
  38. 38.Pace EJ, O'Reilly M. Tickborne diseases: diagnosis and management. Am Fam Physician. 2020;101(9):530-540.
  39. 39.Drexler NA, Dahlgren FS, Heitman KN, et al. National surveillance of spotted fever group rickettsioses in the United States, 2008–2012. Am J Trop Med Hyg. 2016;94(1):26-34.
  40. 40.Phillips J. Rocky Mountain spotted fever. Workplace Health Saf. 2017;65(1):48.
  41. 41.Centers for Disease Control and Prevention. Data and statistics on spotted fever rickettsiosis. May 15, 2024. Accessed December 14, 2025. https://www.cdc.gov/rocky-mountain-spotted-fever/data-research/facts-stats/index.html​
  42. 42.Dantas-Torres F. Rocky Mountain spotted fever. Lancet Infect Dis. 2007;7(11):724-732.
  43. 43.Kirk JL, Fine DP, Sexton DJ, et al. Rocky Mountain spotted fever. A clinical review based on 48 confirmed cases, 1943–1986. Medicine (Baltimore). 1990;69(1):35-45.
  44. 44.Dey P, Mitu MJ, Chakrabarty S, et al. Empirical administration of doxycycline for Rocky Mountain spotted fever: a case report. Cureus. 2023;15(10):e47492.

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.